Next Article in Journal
Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for Osteosarcoma
Next Article in Special Issue
Circulating miRNA Increases the Diagnostic Accuracy of Chromogranin A in Metastatic Pancreatic Neuroendocrine Tumors
Previous Article in Journal
Carotenoids in Cancer Apoptosis—The Road from Bench to Bedside and Back
Previous Article in Special Issue
Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study
Open AccessArticle

Usefulness of FDG-PET/CT-Based Radiomics for the Characterization and Genetic Orientation of Pheochromocytomas Before Surgery

1
Nuclear Medicine Department, University Hospital of Nantes, Place Alexis Ricordeau, 44093 Nantes, France
2
Université de Nantes, CNRS, INSERM, CRCINA, 44007 Nantes, France
3
Endocrinology Department, University Hospital of Nantes, Boulevard Jacques Monod, 44092 Nantes, France
4
Digestive and Endocrine Surgery Department (CCDE), Institut des Maladies de l’Appareil Digestif (IMAD), University Hospital of Nantes, Place Alexis Ricordeau, 44093 Nantes, France
5
Anatomopathology Department, University Hospital of Nantes, Place Alexis Ricordeau, 44093 Nantes, France
6
Genetic Department, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 75015 Paris, France
7
Université de Paris, INSERM, PARCC, 75015 Paris, France
8
Medical Information Department, University Hospital of Nantes, Place Alexis Ricordeau, 44093 Nantes, France
9
Radiology Department, University Hospital of Nantes, Place Alexis Ricordeau, 44093 Nantes, France
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(9), 2424; https://doi.org/10.3390/cancers12092424
Received: 13 June 2020 / Revised: 20 August 2020 / Accepted: 21 August 2020 / Published: 26 August 2020
(This article belongs to the Special Issue Advances in Neuroendocrine Neoplasms Research)
Around 40% of patients with pheochromocytomas (PHEO) carry a germline mutation. Early germline mutation identification is important for accurate treatment and follow-up in affected patients. The aim of our retrospective study was to assess the potential added value of FDG-PET/CT radiomics for the characterization of PHEO and their genetic orientation prior to surgery and genetic testing. We confirmed in an homogeneous population of 52 PHEO (49 patients) the usual avidity of these tumors for FDG (92%) and the impact of germline mutation on their phenotypic presentations with higher SUVmax observed in Cluster-1-related genes. Radiomics biomarkers provided valuable additional and independent information for discriminating genetically determined PHEO (Cluster-1 or Cluster-2-related genes) as well as sporadic forms. FDG-PET/CT is then useful for preoperative detection of PHEO, and when combined with texture features, provides evidences for a genetic predisposition.
Purpose: To assess the potential added value of FDG-PET/CT radiomics for the characterization of pheochromocytomas (PHEO) and their genetic orientation prior to surgery and genetic testing. Methods: This retrospective monocentric study, included 49 patients (52 tumors) that underwent both FDG-PET/CT and MIBG scan before surgery. A germline mutation was secondarily identified in 13 patients in one of the genes related to Cluster 1 (n = 4) or Cluster 2 (n = 9). No mutation was identified in 32 patients and 4 did not have genetic testing. Correlation between several PET-based biomarkers, including SUVmax, metabolic tumor volume (MTV), total lesion glycolysis (TLG) and textural features, and biochemical and genetic features were analyzed. Results: Sensitivity of FDG-PET/CT alone was 92%, and 98% when combined to MIBG. The SUVmax was significantly higher for mutated tumors classified in Cluster 1 than in Cluster 2 (p = 0.002) or for tumors with no identified mutations (p = 0.04). MTV and TLG of the tumors with the most intense uptake discriminated mutated Cluster 2 from sporadic tumors, but not from Cluster 1 tumors. Textural features combined with MTV led to better differentiation between sporadic and mutated tumors (p < 0.05). Conclusion: FDG-PET/CT is useful for preoperative characterization of PHEO, and when combined with radiomics biomarkers, provides evidences for a genetic predisposition. View Full-Text
Keywords: pheochromocytoma; paraganglioma; 18FDG; PET/CT; radiomics; adrenal gland; germline mutation pheochromocytoma; paraganglioma; 18FDG; PET/CT; radiomics; adrenal gland; germline mutation
Show Figures

Figure 1

MDPI and ACS Style

Ansquer, C.; Drui, D.; Mirallié, E.; Renaudin-Autain, K.; Denis, A.; Gimenez-Roqueplo, A.-P.; Leux, C.; Toulgoat, F.; Kraeber-Bodéré, F.; Carlier, T. Usefulness of FDG-PET/CT-Based Radiomics for the Characterization and Genetic Orientation of Pheochromocytomas Before Surgery. Cancers 2020, 12, 2424.

AMA Style

Ansquer C, Drui D, Mirallié E, Renaudin-Autain K, Denis A, Gimenez-Roqueplo A-P, Leux C, Toulgoat F, Kraeber-Bodéré F, Carlier T. Usefulness of FDG-PET/CT-Based Radiomics for the Characterization and Genetic Orientation of Pheochromocytomas Before Surgery. Cancers. 2020; 12(9):2424.

Chicago/Turabian Style

Ansquer, Catherine; Drui, Delphine; Mirallié, Eric; Renaudin-Autain, Karine; Denis, Antoine; Gimenez-Roqueplo, Anne-Paule; Leux, Christophe; Toulgoat, Frederique; Kraeber-Bodéré, Françoise; Carlier, Thomas. 2020. "Usefulness of FDG-PET/CT-Based Radiomics for the Characterization and Genetic Orientation of Pheochromocytomas Before Surgery" Cancers 12, no. 9: 2424.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop